نتایج جستجو برای: myelofibrosis

تعداد نتایج: 4073  

Journal: :Blood 2005
Fabrizio Martelli Barbara Ghinassi Barbara Panetta Elena Alfani Valentina Gatta Alessandro Pancrazzi Costanza Bogani Alessandro Maria Vannucchi Francesco Paoletti Giovanni Migliaccio Anna Rita Migliaccio

All mice harboring the X-linked Gata1low mutation in a predominantly CD1 background are born anemic and thrombocytopenic. They recover from anemia at 1 month of age but remain thrombocytopenic all their life and develop myelofibrosis, a syndrome similar to human idiopathic myelofibrosis, at 12 months. The effects of the genetic background on the myelofibrosis developed by Gata1low mice was asse...

2014
Mario Cazzola Robert Kralovics

Our knowledge of the genetic basis of these disorders began in 2005, when a unique base substitution in JAK2, the gene encoding Janus kinase 2,was found inpatientswith polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The background of our investigations was the previous finding that copy-neutral loss of heterozygosity of chromosome 9p (9pLOH) is the most common chromosom...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2012
John Mascarenhas Ronald Hoffman

The BCR-ABL1-negative myeloproliferative neoplasms (e.g., essential thrombocythemia, polycythemia vera, and primary myelofibrosis) are a group of heterogeneous hematologic malignancies that involve a clonal proliferation of hematopoietic stem cells. Thrombosis, bleeding, and transformation to acute leukemia reduce the overall survival of patients with myelofibrosis, a disease typified by progre...

Journal: :The New England journal of medicine 2012
Claire Harrison Jean-Jacques Kiladjian Haifa Kathrin Al-Ali Heinz Gisslinger Roger Waltzman Viktoriya Stalbovskaya Mari McQuitty Deborah S Hunter Richard Levy Laurent Knoops Francisco Cervantes Alessandro M Vannucchi Tiziano Barbui Giovanni Barosi

BACKGROUND Treatment options for myelofibrosis are limited. We evaluated the efficacy and safety of ruxolitinib, a potent and selective Janus kinase (JAK) 1 and 2 inhibitor, as compared with the best available therapy, in patients with myelofibrosis. METHODS We assigned 219 patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential...

Journal: :Indian Journal of Hematology and Blood Transfusion 2014

2009
Jon van der Walt

The fiftieth anniversary of Blood saw the publication of a series of excellent review articles. The myeloproliferative disorders [1] were first characterised by Gustav Heuck who described myelofibrosis (MF) in 1879. Louis Henri Vaquez described polycythemia vera (PV) in 1892. Essential thrombocythemia (ET) followed somewhat later in 1934 when Emil Epstein and Alfred Goedel recognised it as a di...

Journal: :Drugs of today 2013
Walter Alexander

Key research focused on mantle cell lymphoma, Hodgkin's lymphoma, human immunodeficiency virus-related lymphoma, myelodysplastic syndrome, and myelofibrosis.

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید